HEADER HYDROLASE/HYDROLASE INHIBITOR 09-JAN-12 3VF7 TITLE CRYSTAL STRUCTURE OF HIV-1 PROTEASE MUTANT L76V WITH NOVEL P1'-LIGANDS TITLE 2 GRL-02031 COMPND MOL_ID: 1; COMPND 2 MOLECULE: PROTEASE; COMPND 3 CHAIN: A, B; COMPND 4 FRAGMENT: UNP RESIDUES 501-599; COMPND 5 EC: 3.4.23.16; COMPND 6 ENGINEERED: YES; COMPND 7 MUTATION: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (BRU SOURCE 3 ISOLATE); SOURCE 4 ORGANISM_COMMON: HIV-1; SOURCE 5 ORGANISM_TAXID: 11686; SOURCE 6 GENE: GAG-POL; SOURCE 7 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 8 EXPRESSION_SYSTEM_TAXID: 469008; SOURCE 9 EXPRESSION_SYSTEM_STRAIN: BL21 (DE3); SOURCE 10 EXPRESSION_SYSTEM_VECTOR_TYPE: PLASMID; SOURCE 11 EXPRESSION_SYSTEM_PLASMID: PET11A KEYWDS PROTEASE INHIBITOR, P1'-LIGAND, HYDROLASE-HYDROLASE INHIBITOR COMPLEX EXPDTA X-RAY DIFFRACTION AUTHOR X.X.YU,Y.F.WANG,Y.C.E.CHANG,I.T.WEBER REVDAT 4 13-SEP-23 3VF7 1 REMARK SEQADV LINK REVDAT 3 25-MAR-15 3VF7 1 JRNL REVDAT 2 28-NOV-12 3VF7 1 REMARK REVDAT 1 21-NOV-12 3VF7 0 JRNL AUTH Y.C.CHANG,X.YU,Y.ZHANG,Y.TIE,Y.F.WANG,S.YASHCHUK,A.K.GHOSH, JRNL AUTH 2 R.W.HARRISON,I.T.WEBER JRNL TITL POTENT ANTIVIRAL HIV-1 PROTEASE INHIBITOR GRL-02031 ADAPTS JRNL TITL 2 TO THE STRUCTURES OF DRUG RESISTANT MUTANTS WITH ITS JRNL TITL 3 P1'-PYRROLIDINONE RING. JRNL REF J.MED.CHEM. V. 55 3387 2012 JRNL REFN ISSN 0022-2623 JRNL PMID 22401672 JRNL DOI 10.1021/JM300072D REMARK 2 REMARK 2 RESOLUTION. 1.30 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : SHELXL-97 REMARK 3 AUTHORS : G.M.SHELDRICK REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 1.30 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 10.00 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 COMPLETENESS FOR RANGE (%) : 98.1 REMARK 3 CROSS-VALIDATION METHOD : FREE R REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT (NO CUTOFF). REMARK 3 R VALUE (WORKING + TEST SET, NO CUTOFF) : 0.158 REMARK 3 R VALUE (WORKING SET, NO CUTOFF) : 0.156 REMARK 3 FREE R VALUE (NO CUTOFF) : 0.195 REMARK 3 FREE R VALUE TEST SET SIZE (%, NO CUTOFF) : 5.000 REMARK 3 FREE R VALUE TEST SET COUNT (NO CUTOFF) : 2801 REMARK 3 TOTAL NUMBER OF REFLECTIONS (NO CUTOFF) : 56115 REMARK 3 REMARK 3 FIT/AGREEMENT OF MODEL FOR DATA WITH F>4SIG(F). REMARK 3 R VALUE (WORKING + TEST SET, F>4SIG(F)) : 0.137 REMARK 3 R VALUE (WORKING SET, F>4SIG(F)) : 0.135 REMARK 3 FREE R VALUE (F>4SIG(F)) : 0.172 REMARK 3 FREE R VALUE TEST SET SIZE (%, F>4SIG(F)) : 5.000 REMARK 3 FREE R VALUE TEST SET COUNT (F>4SIG(F)) : 2151 REMARK 3 TOTAL NUMBER OF REFLECTIONS (F>4SIG(F)) : 43209 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 1510 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 77 REMARK 3 SOLVENT ATOMS : 190 REMARK 3 REMARK 3 MODEL REFINEMENT. REMARK 3 OCCUPANCY SUM OF NON-HYDROGEN ATOMS : 1726.0 REMARK 3 OCCUPANCY SUM OF HYDROGEN ATOMS : 1649.7 REMARK 3 NUMBER OF DISCRETELY DISORDERED RESIDUES : 21 REMARK 3 NUMBER OF LEAST-SQUARES PARAMETERS : 17044 REMARK 3 NUMBER OF RESTRAINTS : 22325 REMARK 3 REMARK 3 RMS DEVIATIONS FROM RESTRAINT TARGET VALUES. REMARK 3 BOND LENGTHS (A) : 0.012 REMARK 3 ANGLE DISTANCES (A) : 0.032 REMARK 3 SIMILAR DISTANCES (NO TARGET VALUES) (A) : 0.000 REMARK 3 DISTANCES FROM RESTRAINT PLANES (A) : 0.030 REMARK 3 ZERO CHIRAL VOLUMES (A**3) : 0.061 REMARK 3 NON-ZERO CHIRAL VOLUMES (A**3) : 0.067 REMARK 3 ANTI-BUMPING DISTANCE RESTRAINTS (A) : 0.026 REMARK 3 RIGID-BOND ADP COMPONENTS (A**2) : 0.004 REMARK 3 SIMILAR ADP COMPONENTS (A**2) : 0.056 REMARK 3 APPROXIMATELY ISOTROPIC ADPS (A**2) : 0.079 REMARK 3 REMARK 3 BULK SOLVENT MODELING. REMARK 3 METHOD USED: NULL REMARK 3 REMARK 3 STEREOCHEMISTRY TARGET VALUES : ENGH AND HUBER REMARK 3 SPECIAL CASE: NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: ANISOTROPIC REFINEMENT REDUCED FREE R REMARK 3 (NO CUTOFF) BY ? REMARK 4 REMARK 4 3VF7 COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 17-JAN-12. REMARK 100 THE DEPOSITION ID IS D_1000069969. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 18-FEB-09 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : 4.2-5.4 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : APS REMARK 200 BEAMLINE : 22-ID REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1 REMARK 200 MONOCHROMATOR : SI 220 CHANNEL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : MARMOSAIC 300 MM CCD REMARK 200 INTENSITY-INTEGRATION SOFTWARE : HKL-2000 REMARK 200 DATA SCALING SOFTWARE : HKL-2000 REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 56338 REMARK 200 RESOLUTION RANGE HIGH (A) : 1.300 REMARK 200 RESOLUTION RANGE LOW (A) : 50.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : NULL REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 98.1 REMARK 200 DATA REDUNDANCY : 5.800 REMARK 200 R MERGE (I) : 0.09400 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 14.3000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 1.30 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 1.35 REMARK 200 COMPLETENESS FOR SHELL (%) : 86.3 REMARK 200 DATA REDUNDANCY IN SHELL : 2.70 REMARK 200 R MERGE FOR SHELL (I) : 0.41100 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : 2.100 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: MOLREP REMARK 200 STARTING MODEL: 2IEN REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 53.99 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.30 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 0.9 - 1.2 M NACL/NAOAC BUFFER AT REMARK 280 PH=4.2-5.4. THE RATIO FOR PROTEIN/INHIBITOR IS 1:5, VAPOR REMARK 280 DIFFUSION, HANGING DROP, TEMPERATURE 298K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 21 21 2 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,-Y,Z REMARK 290 3555 -X+1/2,Y+1/2,-Z REMARK 290 4555 X+1/2,-Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 28.91000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 43.12100 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 0.00000 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 28.91000 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 43.12100 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 5600 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 9740 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -67.0 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: COVALENT BOND ANGLES REMARK 500 REMARK 500 THE STEREOCHEMICAL PARAMETERS OF THE FOLLOWING RESIDUES REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED VALUES BY MORE REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,A3,1X,A1,I4,A1,3(1X,A4,2X),12X,F5.1) REMARK 500 REMARK 500 EXPECTED VALUES PROTEIN: ENGH AND HUBER, 1999 REMARK 500 EXPECTED VALUES NUCLEIC ACID: CLOWNEY ET AL 1996 REMARK 500 REMARK 500 M RES CSSEQI ATM1 ATM2 ATM3 REMARK 500 ARG B 57 CD - NE - CZ ANGL. DEV. = 8.7 DEGREES REMARK 500 REMARK 500 REMARK: NULL REMARK 620 REMARK 620 METAL COORDINATION REMARK 620 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 620 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE): REMARK 620 REMARK 620 COORDINATION ANGLES FOR: M RES CSSEQI METAL REMARK 620 NA A 202 NA REMARK 620 N RES CSSEQI ATOM REMARK 620 1 HOH A1016 O REMARK 620 2 HOH A1041 O 88.4 REMARK 620 3 HOH A1063 O 91.0 87.3 REMARK 620 4 HOH A1071 O 79.0 162.8 81.4 REMARK 620 5 HOH A1076 O 178.4 93.2 89.1 99.5 REMARK 620 6 HOH A1105 O 82.6 101.5 169.0 88.5 97.1 REMARK 620 N 1 2 3 4 5 REMARK 620 REMARK 620 COORDINATION ANGLES FOR: M RES CSSEQI METAL REMARK 620 NA B 501 NA REMARK 620 N RES CSSEQI ATOM REMARK 620 1 ASP B 60 O REMARK 620 2 HOH B 630 O 105.5 REMARK 620 3 HOH B 631 O 96.4 74.0 REMARK 620 4 HOH B 632 O 76.7 103.5 171.9 REMARK 620 5 HOH B 634 O 167.0 87.2 84.6 103.1 REMARK 620 6 HOH B 674 O 90.9 158.3 90.4 94.0 76.2 REMARK 620 N 1 2 3 4 5 REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE 031 A 201 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE NA A 202 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC3 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE CL A 203 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC4 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE CL A 204 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC5 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE GOL A 205 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC6 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE GOL A 206 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC7 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE GOL A 207 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC8 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE GOL A 208 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC9 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE NA B 501 REMARK 800 REMARK 800 SITE_IDENTIFIER: BC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE CL B 502 REMARK 800 REMARK 800 SITE_IDENTIFIER: BC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE GOL B 503 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 3H5B RELATED DB: PDB REMARK 900 WILD TYPE HIV-1 PROTEASE WITH NOVEL P1'-LIGANDS GRL-02031 REMARK 900 RELATED ID: 3VF5 RELATED DB: PDB REMARK 900 HIV-1 PROTEASE MUTANT I47V WITH NOVEL P1'-LIGANDS GRL-02031 REMARK 900 RELATED ID: 3VFA RELATED DB: PDB REMARK 900 HIV-1 PROTEASE MUTANT V82A WITH NOVEL P1'-LIGANDS GRL-02031 REMARK 900 RELATED ID: 3VFB RELATED DB: PDB REMARK 900 HIV-1 PROTEASE MUTANT N88D WITH NOVEL P1'-LIGANDS GRL-02031 DBREF 3VF7 A 1 99 UNP P03367 POL_HV1BR 501 599 DBREF 3VF7 B 1 99 UNP P03367 POL_HV1BR 501 599 SEQADV 3VF7 LYS A 7 UNP P03367 GLN 507 ENGINEERED MUTATION SEQADV 3VF7 ILE A 33 UNP P03367 LEU 533 ENGINEERED MUTATION SEQADV 3VF7 ILE A 63 UNP P03367 LEU 563 ENGINEERED MUTATION SEQADV 3VF7 ALA A 67 UNP P03367 CYS 567 ENGINEERED MUTATION SEQADV 3VF7 VAL A 76 UNP P03367 LEU 576 ENGINEERED MUTATION SEQADV 3VF7 ALA A 95 UNP P03367 CYS 595 ENGINEERED MUTATION SEQADV 3VF7 LYS B 7 UNP P03367 GLN 507 ENGINEERED MUTATION SEQADV 3VF7 ILE B 33 UNP P03367 LEU 533 ENGINEERED MUTATION SEQADV 3VF7 ILE B 63 UNP P03367 LEU 563 ENGINEERED MUTATION SEQADV 3VF7 ALA B 67 UNP P03367 CYS 567 ENGINEERED MUTATION SEQADV 3VF7 VAL B 76 UNP P03367 LEU 576 ENGINEERED MUTATION SEQADV 3VF7 ALA B 95 UNP P03367 CYS 595 ENGINEERED MUTATION SEQRES 1 A 99 PRO GLN ILE THR LEU TRP LYS ARG PRO LEU VAL THR ILE SEQRES 2 A 99 LYS ILE GLY GLY GLN LEU LYS GLU ALA LEU LEU ASP THR SEQRES 3 A 99 GLY ALA ASP ASP THR VAL ILE GLU GLU MET SER LEU PRO SEQRES 4 A 99 GLY ARG TRP LYS PRO LYS MET ILE GLY GLY ILE GLY GLY SEQRES 5 A 99 PHE ILE LYS VAL ARG GLN TYR ASP GLN ILE ILE ILE GLU SEQRES 6 A 99 ILE ALA GLY HIS LYS ALA ILE GLY THR VAL VAL VAL GLY SEQRES 7 A 99 PRO THR PRO VAL ASN ILE ILE GLY ARG ASN LEU LEU THR SEQRES 8 A 99 GLN ILE GLY ALA THR LEU ASN PHE SEQRES 1 B 99 PRO GLN ILE THR LEU TRP LYS ARG PRO LEU VAL THR ILE SEQRES 2 B 99 LYS ILE GLY GLY GLN LEU LYS GLU ALA LEU LEU ASP THR SEQRES 3 B 99 GLY ALA ASP ASP THR VAL ILE GLU GLU MET SER LEU PRO SEQRES 4 B 99 GLY ARG TRP LYS PRO LYS MET ILE GLY GLY ILE GLY GLY SEQRES 5 B 99 PHE ILE LYS VAL ARG GLN TYR ASP GLN ILE ILE ILE GLU SEQRES 6 B 99 ILE ALA GLY HIS LYS ALA ILE GLY THR VAL VAL VAL GLY SEQRES 7 B 99 PRO THR PRO VAL ASN ILE ILE GLY ARG ASN LEU LEU THR SEQRES 8 B 99 GLN ILE GLY ALA THR LEU ASN PHE HET 031 A 201 50 HET NA A 202 1 HET CL A 203 1 HET CL A 204 1 HET GOL A 205 6 HET GOL A 206 6 HET GOL A 207 12 HET GOL A 208 6 HET NA B 501 1 HET CL B 502 1 HET GOL B 503 6 HETNAM 031 (3AS,5R,6AR)-HEXAHYDRO-2H-CYCLOPENTA[B]FURAN-5-YL [(1S, HETNAM 2 031 2R)-1-BENZYL-2-HYDROXY-3-([(4-METHOXYPHENYL) HETNAM 3 031 SULFONYL]{[(2R)-5-OXOPYRROLIDIN-2-YL]METHYL}AMINO) HETNAM 4 031 PROPYL]CARBAMATE HETNAM NA SODIUM ION HETNAM CL CHLORIDE ION HETNAM GOL GLYCEROL HETSYN GOL GLYCERIN; PROPANE-1,2,3-TRIOL FORMUL 3 031 C30 H39 N3 O8 S FORMUL 4 NA 2(NA 1+) FORMUL 5 CL 3(CL 1-) FORMUL 7 GOL 5(C3 H8 O3) FORMUL 14 HOH *190(H2 O) HELIX 1 1 GLY A 86 THR A 91 1 6 HELIX 2 2 GLY B 86 THR B 91 1 6 HELIX 3 3 GLN B 92 GLY B 94 5 3 SHEET 1 A 4 GLN A 2 ILE A 3 0 SHEET 2 A 4 THR B 96 ASN B 98 -1 O LEU B 97 N ILE A 3 SHEET 3 A 4 THR A 96 ASN A 98 -1 N THR A 96 O ASN B 98 SHEET 4 A 4 GLN B 2 ILE B 3 -1 O ILE B 3 N LEU A 97 SHEET 1 B 8 LYS A 43 GLY A 49 0 SHEET 2 B 8 GLY A 52 ILE A 66 -1 O GLN A 58 N LYS A 43 SHEET 3 B 8 HIS A 69 VAL A 77 -1 O HIS A 69 N ILE A 66 SHEET 4 B 8 VAL A 32 ILE A 33 1 N ILE A 33 O VAL A 76 SHEET 5 B 8 ASN A 83 ILE A 85 -1 O ILE A 84 N VAL A 32 SHEET 6 B 8 GLN A 18 LEU A 24 1 N LEU A 23 O ILE A 85 SHEET 7 B 8 LEU A 10 ILE A 15 -1 N ILE A 13 O LYS A 20 SHEET 8 B 8 GLY A 52 ILE A 66 -1 O GLU A 65 N LYS A 14 SHEET 1 C 8 TRP B 42 GLY B 49 0 SHEET 2 C 8 GLY B 52 ILE B 66 -1 O GLN B 58 N LYS B 43 SHEET 3 C 8 HIS B 69 VAL B 77 -1 O HIS B 69 N ILE B 66 SHEET 4 C 8 THR B 31 ILE B 33 1 N THR B 31 O VAL B 76 SHEET 5 C 8 ILE B 84 ILE B 85 -1 O ILE B 84 N VAL B 32 SHEET 6 C 8 GLN B 18 LEU B 24 1 N LEU B 23 O ILE B 85 SHEET 7 C 8 LEU B 10 ILE B 15 -1 N ILE B 13 O LYS B 20 SHEET 8 C 8 GLY B 52 ILE B 66 -1 O GLU B 65 N LYS B 14 LINK NA NA A 202 O HOH A1016 1555 1555 2.69 LINK NA NA A 202 O HOH A1041 1555 1555 2.29 LINK NA NA A 202 O HOH A1063 1555 1555 2.38 LINK NA NA A 202 O HOH A1071 1555 1555 2.44 LINK NA NA A 202 O HOH A1076 1555 1555 2.18 LINK NA NA A 202 O HOH A1105 1555 1555 2.50 LINK O ASP B 60 NA NA B 501 1555 1555 2.46 LINK NA NA B 501 O HOH B 630 1555 1555 2.18 LINK NA NA B 501 O HOH B 631 1555 1555 2.63 LINK NA NA B 501 O HOH B 632 1555 1555 2.44 LINK NA NA B 501 O HOH B 634 1555 1555 2.87 LINK NA NA B 501 O HOH B 674 1555 1555 2.42 SITE 1 AC1 25 LEU A 23 ASP A 25 GLY A 27 ALA A 28 SITE 2 AC1 25 ASP A 29 ASP A 30 GLY A 48 GLY A 49 SITE 3 AC1 25 ILE A 50 PRO A 81 VAL A 82 ILE A 84 SITE 4 AC1 25 HOH A1001 HOH A1069 ASP B 25 GLY B 27 SITE 5 AC1 25 ALA B 28 ASP B 30 VAL B 32 GLY B 48 SITE 6 AC1 25 GLY B 49 PRO B 81 VAL B 82 ILE B 84 SITE 7 AC1 25 GOL B 503 SITE 1 AC2 6 HOH A1016 HOH A1041 HOH A1063 HOH A1071 SITE 2 AC2 6 HOH A1076 HOH A1105 SITE 1 AC3 3 TRP A 6 LYS A 55 GOL A 206 SITE 1 AC4 3 THR A 74 ASN A 88 HOH A1015 SITE 1 AC5 8 GLN A 61 GLN A 92 HOH A1006 HOH A1007 SITE 2 AC5 8 HOH A1068 LYS B 45 MET B 46 PHE B 53 SITE 1 AC6 7 THR A 4 TRP A 6 PRO A 44 LYS A 55 SITE 2 AC6 7 CL A 203 HOH A1042 HOH A1046 SITE 1 AC7 10 THR A 12 GLU A 65 ILE A 66 ALA A 67 SITE 2 AC7 10 GLY A 68 HOH A1037 HOH A1084 GLN B 18 SITE 3 AC7 10 MET B 36 SER B 37 SITE 1 AC8 5 GLY A 40 HOH A1025 HOH A1071 LYS B 70 SITE 2 AC8 5 ALA B 71 SITE 1 AC9 6 ASP B 60 HOH B 630 HOH B 631 HOH B 632 SITE 2 AC9 6 HOH B 634 HOH B 674 SITE 1 BC1 3 ARG A 41 THR B 74 ASN B 88 SITE 1 BC2 4 031 A 201 HOH A1039 ARG B 8 VAL B 82 CRYST1 57.820 86.242 46.005 90.00 90.00 90.00 P 21 21 2 8 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.017295 0.000000 0.000000 0.00000 SCALE2 0.000000 0.011595 0.000000 0.00000 SCALE3 0.000000 0.000000 0.021737 0.00000